Development of purine-scaffold small molecule inhibitors of Hsp90

Current Cancer Drug Targets

Volumn 3, Issue 5, 2003, Pages 371-376

  Chiosis, Gabriela ^a   Lucas, Brian ^a   Huezo, Henri ^a   Solit, David ^a   Basso, Andrea ^a   Rosen, Neal ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; ANTINEOPLASTIC AGENT; GELDANAMYCIN; HEAT SHOCK PROTEIN 90 INHIBITOR; PROTEIN INHIBITOR; PURINE DERIVATIVE; RADICICOL; UNCLASSIFIED DRUG;

CANCER CELL; CELL FUNCTION; CLINICAL TRIAL; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; DRUG INHIBITION; DRUG PROTEIN BINDING; DRUG SENSITIVITY; DRUG SOLUBILITY; DRUG SYNTHESIS; HUMAN; IC 50; NEOPLASM; NONHUMAN; PHENOTYPE; REVIEW; STRESS;

ANIMALS; DRUG DESIGN; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MODELS, MOLECULAR; PURINES;

EID: 0141485327     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568009033481778     Document Type: Review

References (38)

1. Buchner, J. Hsp90 & Co. - A Holding for Folding. Trends Biochem. Sci. 1999, 4, 136-144.
2. Toft, O. D. Recent Advances in the Study of Hsp90 Structure and Mechanism of Action. Trends Endocrinol. Med. 1998, 9, 238-243.
3. Scheibel, T.; Buchner, J. The Hsp90 Complex - A Super-Chaperone Machine as a Novel Drug Target. Biochem. Pharmacol. 1998, 56, 675-682.
4. Neckers, L. Hsp90 Inhibitors as Novel Cancer Chemotherapeutic Agents. Trends Mol. Med. 2002, 8, S55-S61.
5. Workman, P.; Maloney, A. HSP90 as a New Therapeutic Target for Cancer Therapy: the Story Unfolds. Expert Opin. Biol. Ther. 2002, 2, 3-24.
6. Yamazaki, M.; Akaogi, K.; Miwa, T.; Imai, T.; Soeda, E.; Yokoyama, K. Nucleotide Sequence of a Full-Length cDNA for 90 kDa Heat-Shock Protein from Human Peripheral Blood Lymphocytes. Nucleic Acids Res. 1989, 17, 7108.
7. Rebbe, N. F.; Ware, J. Bertina, R. M.; Modrich, P.; Stafford, D. W. Nucleotide Sequence of a cDNA for a Member of the Human 90-KDa Heat-Shock Protein Family. Gene. 1987, 53, 235-245.
8. Argon, Y.; Simen, B. B. GRP94, an ER Chaperone with Protein and Peptide Binding Properties. Semin. Cell Dev. Biol. 1999, 5, 495-505.
9. Felts, S. J.; Owen, B. A.; Nguyen, P.; Trepel, J.; Donner, D. B.; Toft, D. O. The Hsp90-Related Protein TRAP1 is a Mitochondrial Protein with Distinct Functional Properties. J. Biol. Chem. 2000, 275, 3305-3312.
10. Prodromou, C.; Roe, S. M.; Piper, P. W.; Pearl, L. H. A Molecular Clamp in the Crystal Structure of the N-Terminal Domain of the Yeast Hsp90 Chaperone. Nat. Struct. Biol. 1997, 6, 477-482.
11. Prodromou, C.; Roe, S. M.; O'Brien, R.; Ladbury, J. E.; Piper, P. W.; Pearl, L. H. Identification and Structural Characterization of the ATP/ADP-Binding Site in the Hsp90 Molecular Chaperone. Cell 1997, 90, 65-75.
12. Obermann, W. M.; Sondermann, H.; Russo, A. A.; Pavletich, N. P.; Hartl, F. U. In Vivo Function of Hsp90 Is Dependent On ATP Binding and ATP Hydrolysis. J. Cell Biol. 1998, 143, 901-910.
13. Panaretou, B.; Prodromou, C.; Roe, S. M.; O'Brien, R.; Ladbury, J. E.; Piper, P. W.; Pearl, L. H. ATP Binding and Hydrolysis Are Essential to the Function of the Hsp90 Molecular Chaperone in Vivo. EMBO J. 1998, 17, 4829-4836.
14. Bergerat, A.; De Massy, B.; Gadelle, D.; Varoutas, P. C.; Nicolas, A.; Forterre, P. an Atypical Topoisomerase 11 from Archaea with Implications for Meiotic Recombination. Nature 1997, 386, 414-417.
15. Mushegian, A. R.; Bassett, D. E. Jr.; Boguski, M. S.; Bork, P.; Koonin, E. V. Positionally Cloned Human Disease Genes: Patterns of Evolutionary Conservation and Functional Motifs. Proc. Natl. Acad. Sci. USA 1997, 94, 5831-5836.
16. Dutta, R.; Inouye, M. GHKL, an Emergent Atpase/Kinase Superfamily. Trends Biochem. Sci. 2000, 25, 24-28.
17. Stebbins, C. E.; Russo, A. A.; Schneider, C.; Rosen, N.; Hartl, F. U., Pavletich, N. P. Crystal Structure of an Hsp90-Geldanamycin Complex: Targeting of a Protein Chaperone by an Antitumor Agent. Cell 1997, 89, 239-250.
18. Schulte, T. W.; Akinaga, S.; Soga, S.; Sullivan, W.; Stensgard, B.; Toft, D.; Neckers, L. M. Antibiotic Radicicol Binds to the N-Terminal Domain of Hsp90 and Shares Important Biologic Activities with Geldanamycin. Cell Stress Chap. 1998, 2, 100-108.
19. Roe, S. M.; Prodromou, C.; O'Brien, R.; Ladbury, J. E.; Piper, P. W.; Pearl, L. H. Structural Basis for Inhibition of the Hsp90 Molecular Chaperone by the Antitumor Antibiotics Radicicol and Geldanamycin. J. Med. Chem. 1999, 42, 260-266.
20. Uehara, Y.; Fukazawa, H.; Murakami, Y.; Mizuno, S. Irreversible Inhibition of V-Src Tyrosine Kinase Activity by Herbimycin a and Its Abrogation by Sulfhydryl Compounds. Biochem. Biophys. Res. Commun. 1989, 163, 803-809.
21. Supko, J. G.; Hickman, R. L.; Grever, M. R.; Malspeis, L. Preclinical Pharmacological Evaluation of Geldanamycin as an Antitumor Agent. Cancer Chemother. Pharmacol. 1995, 36, 305-315.
22. Schulte, T. W.; Neckers, L. M. The Benzoquinone Ansamycin 17-Allylamino-17-Demethoxygeldanamycin Binds to Hsp90 and Shares Important Biologic Activities with Geldanamycin. Cancer Chemother. Pharmacol. 1998, 42, 273-279.
23. Kelland, L. R.; Sharp, S. Y.; Rogers, P. M.; Myers, T. G.; Workman, P. DT-Diaphorase Expression and Tumor Cell Sensitivity to 17-Allyamino-17-Demethoxygeldanamycin, an Inhibitor of Heat Shock Protein 90. J. Natl. Cancer Inst. 1999, 91, 1940-1949.
24. Shiotsu, Y.; Neckers, L. M.; Wortman, I.; An, W. G.; Schulte, T. W.; Soga, S.; Murakata, C.; Tamaoki, T.; Akinaga, S. Novel Oxime Derivatives of Radicicol Induce Erythroid Differentiation Associated with Preferential G(1) Phase Accumulation against Chronic Myelogenous Leukemia Cells Through Destabilization of Bcr-Abl with Hsp90 Complex. Blood 2000, 96, 2284-2291.
25. Soga, S.; Neckers, L. M.; Schulte, T. W.; Shiotsu, Y.; Akasaka, K.; Narumi, H.; Agatsuma, T.; Ikuina, Y.; Murakata, C.; Tamaoki, T.; Akinaga, S. Novel Oxime Derivatives of Radicicol Induce Erythroid Differentiation Associated with Preferential G(1) Phase Accumulation against Chronic Myelogenous Leukemia Cells through Destabilization of Bcr-Abl with Hsp90 Complex. Cancer Res. 1999, 59, 2931-2938.
26. Kurebayashi, J.; Otsuki, T.; Kurosumi, M.; Soga, S.; Akinaga, S.; Sonoo, H. A Radicicol Derivative, KF58333, Inhibits Expression of Hypoxia-Inducible Factor-1alpha and Vascular Endothelial Growth Factor, Angiogenesis and Growth of Human Breast Cancer Xenografts. Jpn. J. Cancer Res. 2001, 92, 1342-1351.
27. Soga, S.; Sharma, S. V.; Shiotsu, Y.; Shimizu, M.; Tahara, H.; Yamaguchi, K.; Ikuina, Y.; Murakata, C.; Tamaoki, T.; Kurebayashi, J.; Schulte, T. W.; Neckers, L. M.; Akinaga, S. Stereospecific Antitumor Activity of Radicicol Oxime Derivatives. Cancer Chemother. Pharmacol. 2001, 48, 435-445.
28. Schnur, R. C.; Corman, M. L.; Gallaschun, R. J.; Cooper, B. A.; Dee, M. F.; Doty, J. L.; Muzzi, M. L.; Moyer, J. D.; Diorio, C. I.; Barbacci, E. G.; Miller, P. E.; O'Brien, A. T.; Morin, M. J.; Foster, B. A.; Pollack, V. A.; Savage, D. M.; Sloan, D. E.; Pustilnik, L. R.; Moyer, M. P. Inhibition of the Oncogene Product p185erbb-2 in Vitro and in Vivo by Geldanamycin and Dihydrogeldanamycin Derivatives J. Med. Chem. 1995, 38, 3806-3812.
29. Schnur, R. C.; Corman, M. L.; Gallaschun, R. J.; Cooper, B. A.; Dee, M. F.; Doty, J. L.; Mumi, M. L.; Diorio, C. I.; Barbacci, E. G.; Miller, P. E., Pollack, V. A.; Savage, D. M.; Sloan, D. E.; Pustilnik, L. R.; Moyer, J. D.; Moyer, M. P. Erbb-2 Oncogene Inhibition by Geldanamycin Derivatives: Synthesis, Mechanism of Action, and Structure-Activity Relationships. J. Med. Chem. 1996, 38, 3813-3820.
30. Rowlands, M. G.; Newbatt, Y. M.; Turlais, F.; Prodromou, C.; Pearl, L.; Workman, P.; Aherne, W. High Throughput Screening Assay for Inhibitors of Heat-Shock Protein 90 ATPase Activity. Clinic. Cancer Res. 2001, 7, 475 Suppl. S.
31. Chiosis, G.; Timaul, M. N.; Lucas, B.; Munster, M. N.; Zheng, F. F.; Sepp-Lorenzino, L.; Rosen, N. A Small Molecule Designed to Bind to the Adenine Nucleotide Pocket of Hsp90 Causes Her2 Degradation and the Growth Arrest and Differentiation of Breast Cancer Cells. Chem. Biol. 2001, 8, 289-299.
32. Ki, S. W.; Ishigami, K.; Kitahara, T.; Kasahara, K.; Yoshida, M.; Horinouchi, S. Radicicol Binds and Inhibits the Mammalian ATP Citrate Lyase. J. Biol. Chem. 2000, 275, 39231-39236.
33. Lipinski, C. A.; Lombardo, F.; Dominy, B. W., Feeney, P. J. Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Developmental Settings. Adv. Drug Deliv. Rev. 1997, 23, 3-25,
34. Lucas, B.; Rosen, N.; Chiosis, G. Facile Synthesis of 9-Alkyl-8-Benzyl-9H-Purin-6-Ylamine Derivatives. J. Comb. Chem. 2001, 3, 518-520.
35. Rinehart, K. L. Jr.; Shield, L. S. Chemistry of the Ansamycin Antibiotics. Forschr. Chem. Org. Naturst. 1976, 33, 231-307.
36. Chiosis, G.; Huezo, H; Lucas, B; Rosen, N. Development of a Purine-Based Novel Class of Hsp90 Binders That Inhibit the Proliferation of Cancer Cells and Induce the Degradation of Her2 Tyrosine Kinase. Bioorg. Med. Chem. 2002, 10, 3555-3564.
37. Chiosis, G.; Shtil, A.; Lucas, B.; Huezo, H.; Rosen, N. Development of 9-Alkyl-8-Benzyl-9H-Purin-6-Ylamines as Inhibitors of the Hsp90 Family. Clinic. Cancer Res. 2001, 7, 474 Suppl. S.
38. Chiosis, G.; Huezo, H.; Rosen, N.; Mimnaugh, E.; Whitesell, L.; Neckers, L. 17AAG - Low Target Binding Affinity and Potent Cell Activity: Finding an Explanation. [Apparent and Real Potency of Ansamycins: Which One Is to Trust?]. Mol. Cancer Ther. 2003, 2, 123-219.